Human Peripheral Blood Macrophages As a Model for Studying Glucocerebrosidase Dysfunction


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Decreased activity of glucocerebrosidase (GCase) as a result of mutations in the GBA gene causes Gaucher’s disease (GD), which belongs to the group of lysosomal storage disorders. The risk of Parkinson’s disease in homo- and heterozygous carriers of GBA mutations is elevated seven- to eightfold. Screening of novel compounds designed to enhance GCase activity requires development of in vitro models based on primary cell cultures obtained from patients carrying GBA mutations. In this work, the efficiency of different methods used to culture peripheral blood macrophages of GD patients and control subjects was compared, and GCase activity and lysosphingolipid concentrations were evaluated using tandem mass spectrometry (HPLC‒MS/MS) in dried cell spots. For the first time, the efficacy of restoring the activity of mutant GCase has been assessed in primary macrophages of GD patients cultured in the presence of pharmacological GCase chaperones isofagomine and ambroxol. Based on these results, a convenient method of in vitro screening of candidate pharmacological agents designed to increase GCase activity can be proposed.

Авторлар туралы

M. Nikolaev

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Хат алмасуға жауапты Автор.
Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

A. Kopytova

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Gatchina, Leningrad oblast, 188300

G. Baidakova

Research Center of Medical Genetics

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Moscow, 115522

A. Emel’yanov

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

G. Salogub

Almazov National Medical Research Center, Ministry of Health of the Russian Federation

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, St. Petersburg, 197341

K. Senkevich

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

T. Usenko

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

M. Gorchakova

Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, St. Petersburg, 197022

Yu. Koval’chuk

Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, St. Petersburg, 197022

O. Berkovich

Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, St. Petersburg, 197022

E. Zakharova

Research Center of Medical Genetics

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Moscow, 115522

S. Pchelina

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Ресей, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022


© Pleiades Publishing, Ltd., 2019

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>